2026-07-22T12:31:29Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/184462024-02-19T15:30:47Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Falco, Agustín
author
de Oliveira, Thiago Bueno
author
Cacicedo, Jon
author
Ospina, Aylen Vanessa
author
Ticona, Miguel Ángel
author
Galindo, Héctor
author
Pereira, Marcos David
author
Aguilar-Ponce, José Luis
author
Rueda-Domínguez, Antonio
author
Soria, Tannia
author
Taberna, Miren
author
Iglesias, Lara
author
Sowley, Taysser
author
Mesía, Ricard
author
TTCC group (Spanish Group for the Treatment of the Head and Neck Cancer)
2024-02-19T15:30:47Z
2024-02-19T15:30:47Z
2021-08-26
10.2147/CMAR.S322411
1179-1322
Cancer management and research
http://hdl.handle.net/10668/18490
34471383
http://hdl.handle.net/20.500.12105/18446
Cisplatin is the standard of treatment for squamous cell carcinoma of the head and neck (SCCHN) that has demonstrated efficacy, either in locally advanced disease when combined with radiotherapy at high doses, or in metastatic/recurrent disease when combined with other agents. However, the usual toxicities related to cisplatin, such as neurotoxicity, nephrotoxicity, ototoxicity, and hematologic toxicities, especially when high doses have been administered, have important implications in the patients' quality of life. The decision to administer cisplatin depends on several patient factors, such as age, performance status, weight loss, comorbidities, previous toxicities, chronic viral infection, or even the current SARS-CoV-2 pandemic. In order to establish recommendations for the management of patients with SCCHN, a group of experts in medical and radiation oncology from Spain and Latin-American discussed how to identify patients who are not candidates for cisplatin to offer them the most suitable therapeutic alternative.
eng
age
cisplatin
comorbidities
contraindication
frailty
toxicity
Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice.
research article